Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.38 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.38 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | HRH1 | P35367 | 3/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28158895 | 0.98 | HTR2A (0.56) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL190865 | 0.98 | HTR2A (0.60) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL8782143 | 0.94 | HTR2A (0.52) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8861752 | 0.94 | HTR2A (0.60) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Iodide SCHEMBL4110593 | 0.94 | HTR2A (0.60) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL9147651 | 0.93 | HTR2A (0.50) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL8909571 | 0.92 | HTR2A (0.53) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9549516 | 0.89 | HTR2A (0.53) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL143506 | 0.86 | HIF1A (0.58) | HTR2AHRH1HIF1ACYP1A2CYP2D6 | |
| Acetic Acid SCHEMBL9549706 | 0.84 | HTR2A (0.50) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111548369-B | Method for simply and conveniently preparing high-purity olopatadine hydrochloride intermediate | 内蒙古京东药业有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-115417753-A | Synthetic method of melitracen and intermediate thereof | 重庆西南制药二厂有限责任公司 | 2022-12-02 | — | — | CN | claimed |
| CN-113620920-A | Preparation method of olopatadine hydrochloride | 四川子仁制药有限公司 | 2021-11-09 | — | — | CN | claimed |
| CN-112457287-A | Preparation method of E-olopatadine | 重庆西南制药二厂有限责任公司 | 2021-03-09 | — | — | CN | claimed |
| CN-111548369-A | Method for simply and conveniently preparing high-purity olopatadine hydrochloride intermediate | 内蒙古京东药业有限公司 | 2020-08-18 | — | — | CN | claimed |
| EP-3066087-B1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | LABORATORIO CHIMICO INT S P A (IT) | 2017-10-18 | — | — | EP | claimed |
| US-9708284-B2 | Process for the preparation of olopatadine and sylil intermediates thereof | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2017-07-18 | — | — | US | claimed |
| EP-3066087-A1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | Laboratorio Chimico Internazionale S.p.A. (IT) | 2016-09-14 | — | — | EP | claimed |
| US-20160244425-A1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2016-08-25 | — | — | US | claimed |
| EP-2393797-B1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM SPA (IT) | 2016-04-20 | — | — | EP | claimed |
| WO-2015063579-A1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2015-05-07 | — | — | WO | claimed |
| US-8835655-B2 | Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof | ZACH SYSTEM S.P.A (IT) | 2014-09-16 | — | — | US | claimed |
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2012-01-19 | — | — | US | claimed |
| EP-2393797-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZaCh System S.p.A. (IT) | 2011-12-14 | — | — | EP | claimed |
| WO-2011128911-A2 | IMPROVED PROCESS FOR LL-[(Z)-3-(DIMETHYLAMINO)PROPYIIDENEL-6-LL- DIHYDRODIBENZ[B,EL OXEPIN-2-ACETICACID | MSN LABORATORIES LIMITED (IN) | 2011-10-20 | — | — | WO | claimed |
| WO-2010089268-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2010-08-12 | — | — | WO | claimed |
| EP-2004621-A2 | POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF | Universität Zürich (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007110761-A2 | POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF | Universität Zürich (CH) | 2007-10-04 | — | — | WO | claimed |
| US-20070232814-A1 | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof | UNIVERSITAT ZURICH (CH) | 2007-10-04 | — | — | US | claimed |
| CN-112457287-B | Preparation method of E-olopatadine | 重庆西南制药二厂有限责任公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-115417753-B | Synthesis method of melitracen and intermediate thereof | 重庆西南制药二厂有限责任公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111548369-B | Method for simply and conveniently preparing high-purity olopatadine hydrochloride intermediate | 内蒙古京东药业有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-111548369-B | Method for simply and conveniently preparing high-purity olopatadine hydrochloride intermediate | 内蒙古京东药业有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-115417753-A | Synthetic method of melitracen and intermediate thereof | 重庆西南制药二厂有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-115403473-A | Synthesis method of compound | 重庆西南制药二厂有限责任公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-112375060-B | Post-treatment purification method of olopatadine hydrochloride | 广州健康元呼吸药物工程技术有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-113620920-A | Preparation method of olopatadine hydrochloride | 四川子仁制药有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113620920-A | Preparation method of olopatadine hydrochloride | 四川子仁制药有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-112457287-A | Preparation method of E-olopatadine | 重庆西南制药二厂有限责任公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112375060-A | Post-treatment purification method of olopatadine hydrochloride | 广州健康元呼吸药物工程技术有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-111548369-A | Method for simply and conveniently preparing high-purity olopatadine hydrochloride intermediate | 内蒙古京东药业有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111548369-A | Method for simply and conveniently preparing high-purity olopatadine hydrochloride intermediate | 内蒙古京东药业有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-105693685-B | The preparation process of Olopatadine hydrochloride | 山东罗欣药业集团股份有限公司 | 2018-05-22 | — | — | CN | disclosed |
| EP-3066087-B1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | LABORATORIO CHIMICO INT S P A (IT) | 2017-10-18 | — | — | EP | disclosed |
| US-9708284-B2 | Process for the preparation of olopatadine and sylil intermediates thereof | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2017-07-18 | — | — | US | disclosed |
| CN-106046053-A | Preparation method of [3-(dimethylamino)propyl]triphenylphosphonium bromide hydrobromide | 湖州恒远生物化学技术有限公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-106046053-A | Preparation method of [3-(dimethylamino)propyl]triphenylphosphonium bromide hydrobromide | 湖州恒远生物化学技术有限公司 | 2016-10-26 | — | — | CN | disclosed |
| EP-3066087-A1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | Laboratorio Chimico Internazionale S.p.A. (IT) | 2016-09-14 | — | — | EP | disclosed |
| US-20160244425-A1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| EP-2648707-B1 | HYDROXYLATED TRICYCLIC COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2393797-B1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM SPA (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-9090535-B2 | Hydroxylated tricyclic compounds | NEKTAR THERAPEUTICS (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2015063579-A1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2015-05-07 | — | — | WO | disclosed |
| US-9000195-B2 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA, S.A.U. (ES) | 2015-04-07 | — | — | US | disclosed |
| US-8835655-B2 | Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof | ZACH SYSTEM S.P.A (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20130317114-A1 | Hydroxylated Tricyclic Compounds | NEKTAR THERAPEUTICS (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2666770-A1 | Process for obtaining olopatadine and intermediates | Crystal Pharma S.A.U (ES) | 2013-11-27 | — | — | EP | disclosed |
| EP-2648707-A1 | HYDROXYLATED TRICYCLIC COMPOUNDS | Nektar Therapeutics (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2145882-B1 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA SAU (ES) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012079017-A1 | HYDROXYLATED TRICYCLIC COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2012-01-19 | — | — | US | disclosed |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | disclosed |
| EP-2393797-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZaCh System S.p.A. (IT) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011128911-A2 | IMPROVED PROCESS FOR LL-[(Z)-3-(DIMETHYLAMINO)PROPYIIDENEL-6-LL- DIHYDRODIBENZ[B,EL OXEPIN-2-ACETICACID | MSN LABORATORIES LIMITED (IN) | 2011-10-20 | — | — | WO | disclosed |
| WO-2010089268-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2010-08-12 | — | — | WO | disclosed |
| US-7687646-B2 | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof | AZAD PHARMACEUTICAL INGREDIENTS, AG (CH) | 2010-03-30 | — | — | US | disclosed |
| WO-2010007056-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2010-01-21 | — | — | WO | disclosed |
| EP-2145882-A1 | Process for obtaining olopatadine and intermediates | Ragactives, S.L.U. (ES) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009081417-A2 | PROCESS FOR PREPARATION OF OLOPAT ADINE HYDROCHLORIDE | INDOCO REMEDIES LIMITED (IN) | 2009-07-02 | — | — | WO | disclosed |
| EP-2004621-A2 | POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF | Universität Zürich (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007110761-A2 | POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF | Universität Zürich (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232814-A1 | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof | UNIVERSITAT ZURICH (CH) | 2007-10-04 | — | — | US | disclosed |
| WO-2007105234-A2 | A PROCESS FOR THE PREPARATION OF ISOMERS OF 11-[3-(DIMETHYLAMINO)PROPYLIDENE]-6, 11-DIHYDRODIBENZ [b, e] OXEPIN-2-ACETIC ACID HYDROCHLORIDE AND POLYMORPHS THEREOF | USV LIMITED (IN) | 2007-09-20 | — | — | WO | disclosed |
| EP-0235796-B2 | Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent | KYOWA HAKKO KOGYO KK (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0351887-B1 | Tricyclic aromatic compounds | WELLCOME FOUND (GB) | 1995-07-26 | — | — | EP | disclosed |
| US-5395610-A | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | BURROUGHS-WELLCOME CO. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5300282-A | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | BURROUGHS-WELLCOME COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0316022-B1 | Tricyclic compounds | WELLCOME FOUND (GB) | 1993-11-18 | — | — | EP | disclosed |
| EP-0409406-B1 | ARYL-SUBSTITUTED AMINE DERIVATIVES USEFUL IN CANCER THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-08 | — | — | EP | disclosed |
| EP-0487502-A2 | Pharmaceutically active aryl-substituted amine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-27 | — | — | EP | disclosed |
| US-5116863-A | Antiallergens, antiinflammatory agents; asthma | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-05-26 | — | — | US | disclosed |
| EP-0409406-A2 | Aryl-substituted amine derivatives useful in cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
| WO-1990015599-A1 | MEDICAMENTS USEFUL IN CANCER THERAPY AND HAVING ANTIHISTAMINIC PROPERTIES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-27 | — | — | WO | disclosed |
| US-4923892-A | DOXEPIN DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0214779-B1 | TRICYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0351887-A1 | Tricyclic aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-24 | — | — | EP | disclosed |
| US-4871865-A | ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0316022-A2 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-05-17 | — | — | EP | disclosed |
| EP-0235796-A2 | Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| EP-0214779-A1 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-03-18 | — | — | EP | disclosed |
| US-4533722-A | COPPER CONTAINING COCATALYST | GENERAL ELECTRIC COMPANY (US) | 1985-08-06 | — | — | US | disclosed |
| US-4471105-A | HIGH MOLECULAR WEIGHT POLYMERS FROM STERICALLY HINDERED BISPHENOLS; REUSE AND CIRCULATION OF CATALYST | GENERAL ELECTRIC COMPANY (US) | 1984-09-11 | — | — | US | disclosed |
| US-4384108-A | Two-phase interfacial polycarbonate process | GENERAL ELECTRIC COMPANY (US) | 1983-05-17 | — | — | US | disclosed |
| US-4384108-A | Two-phase interfacial polycarbonate process | GENERAL ELECTRIC COMPANY (US) | 1983-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232814-A1 | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof | HRH4, HRH1, HRH3 | SIGMAR1 875/4885CHRM2 45/4885ADRA2A 29/4885 |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | OXER1, AOC3, OPRD1 | SIGMAR1 100/4885CHRM2 29/4885ADRA2A 27/4885 |
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | QDPR, OPRD1, O60361 | SIGMAR1 759/4885CHRM2 738/4885ADRA2A 52/4885 |
| US-20160244425-A1 | A PROCESS FOR THE PREPARATION OF OLOPATADINE AND SYLIL INTERMEDIATES THEREOF | COMT, PNMT, OPRK1 | SIGMAR1 136/4885CHRM2 724/4885ADRA2A 6/4885 |
| US-20130317114-A1 | Hydroxylated Tricyclic Compounds | ABCG2, UGT1A1, HTT | SIGMAR1 324/4885CHRM2 756/4885ADRA2A 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.